Thrombogenicity of factor IX complex: in vivo investigation.
Factor IX Complex therapy has been associated with thrombosis when used in patients with liver disease, hemophilia B and hemophilia A with inhibitors to Factor VIII when administered repetitively and in high doses. Three mechanisms for inducing thrombogenicity have been proposed: activated coagulants, coagulant-active phospholipid content and/or the high zymogen level attained in recipients. A new animal model using Russel Viper Venom (RVV) as an in vivo stimulus of coagulation has been used to investigate the role of high levels of zymogens in the induction of thrombosis. The quantity of RVV tolerated by rabbits infused with Factor IX Complex is reduced 100-fold. Infusion of Factor X or prothrombin also reduces the lethal dose of RVV. In contrast, Coagulation Factor IX devoid of other coagulants has little effect. However other animal data indicate that the amount of activated coagulants can play a role in the in vivo thrombogenicity of Factor IX Complex.
D000818:Animals; D001779:Blood Coagulation Factors / Q000378:metabolism / Q000633:toxicity*; D004285:Dogs; D007700:Kinetics; D011817:Rabbits; D013927:Thrombosis / Q000209:etiology*
D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates